Nexentis Technologies Inc. (NXTS) Orders Molecules for Planned In-Vitro Testing
Nexentis Technologies' subsidiary MitoCareX ordered molecules for in-vitro testing after computational prioritization. Testing has not yet begun, and results are pending. According to the company, this follows an initial screening announced in October 2026.
